MedPath

Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff

Completed
Conditions
Sars-CoV2
Interventions
Diagnostic Test: Anti-SARS-CoV2 Serology
Other: Questionnaire
Registration Number
NCT04387838
Lead Sponsor
Direction Centrale du Service de Santé des Armées
Brief Summary

Emerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission occurs through droplets, with a R0 of approximately 3.

Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions.

Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced.

This study is aimed at evaluating the incidence rate of anti-SARS-Cov2 seroconversion over 2 months among hospital staff, without any supposed anti-Covid treatment 19.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
845
Inclusion Criteria
  • Army Training Hospital staff
Exclusion Criteria
  • Individuals who have already been confirmed Covid-19 positive
  • Individuals taking preventive anti-Covid-19 therapy or considering participating in anti-Covid-19 therapy study
  • Individuals on hydroxychloroquine
  • Pregnant or breastfeeding women
  • Non-permanent staff during the study period
  • Individuals identified for a detachment outside the metropole during the study period

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Anti-SARS-CoV2 serological statusQuestionnaireAt Day 0, a blood sample is collected by venipuncture and a questionnaire is being filled. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France. For individuals who are anti-SARS-CoV2 seronegative, the same intervention is made at Day 30 and D60. For the individuals who are anti-SARS-CoV2 seropositive, the study follow-up is stopped.
Anti-SARS-CoV2 serological statusAnti-SARS-CoV2 SerologyAt Day 0, a blood sample is collected by venipuncture and a questionnaire is being filled. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France. For individuals who are anti-SARS-CoV2 seronegative, the same intervention is made at Day 30 and D60. For the individuals who are anti-SARS-CoV2 seropositive, the study follow-up is stopped.
Primary Outcome Measures
NameTimeMethod
Anti-SARS-Cov2 seroconversion between Day 0 and Day 60.From Day 0 to Day 60

Change of Anti-SARS-Cov2 serological status between Day 0 and Day 60, measured in blood sample.

Anti-SARS-Cov2 seroconversion between Day 0 and Day 30.From Day 0 to Day 30

Change of Anti-SARS-Cov2 serological status between Day 0 and Day 30, measured in blood sample.

Anti-SARS-Cov2 seroconversion between Day 30 and Day 60.From Day 30 to Day 60

Change of Anti-SARS-Cov2 serological status between Day 30 and Day 60, measured in blood sample.

Secondary Outcome Measures
NameTimeMethod
Anti-SARS-Cov2 seroprevalence at Day 0.Day 0

Anti-SARS-Cov2 seroprevalence measured in blood sample collected at Day 0.

Correlation between seroconversion and socio-demographic factors - sexDay 60

Correlation between seroconversion (measured in blood sample) at Day 60 and sex

Correlation between seroconversion and socio-demographic factors - ageDay 60

Correlation between seroconversion (measured in blood sample) at Day 60 and age

Correlation between seroconversion and professional factors - job typeDay 60

Correlation between seroconversion (measured in blood sample) at Day 60 and job type (nurse, physician, etc.)

Correlation between seroconversion and professional factors - personal protective equipment typeDay 60

Correlation between seroconversion (measured in blood sample) at Day 60 and personal protective equipment type

Correlation between seroconversion and non-professional factors - contact with infected individualsDay 60

Correlation between seroconversion (measured in blood sample) at Day 60 and contact with infected individuals

Correlation between seroconversion and non-professional factors - wearing of professional equipmentDay 60

Correlation between seroconversion (measured in blood sample) at Day 60 and wearing of professional equipment

Correlation between seroconversion and non-professional factors - respect of barrier gesturesDay 60

Correlation between seroconversion (measured in blood sample) at Day 60 and respect of barrier gestures

Trial Locations

Locations (2)

Hôpital d'Instuction des Armées Sainte-Anne

🇫🇷

Toulon, France

Hôpital d'Instruction des Armées Robert Picqué

🇫🇷

Villenave-d'Ornon, France

© Copyright 2025. All Rights Reserved by MedPath